U.S. fights Pfizer; Tripos buys Pharsight;

> Pfizer is having a tough time with its Quigley unit reorganization, since the government is questioning the basis of the company's bankruptcy filing. Report

> Informatics company Tripos is buying Pharsight Corporation, which markets software, strategic and regulatory services. Tripos is forking over $5.50 per share--a 29 percent premium over yesterday's closing price. In total, the deal is worth $57 million. Report

> How low can 23andMe go? Lower than $999, apparently. The Google-backed genetic screening company has slashed the price of its Personal Genome Service test, which analyzes patients for inherited traits and provides an idea of their personal disease risks. Report

> Advanced Cell Technologies is restructuring. The company has been on the rocks since it saw stock prices nosedive in July. Now they're looking to save $5 million to $6 million a year by streamlining and focusing on its most advanced clinical program. Report

> Pfizer and Ligand's osteoporosis drug Fablyn got the green light from an FDA advisory panel by a margin of nine to three. Report

> Bristol-Myers Squibb and AstraZeneca presented results from a 24-week Phase III study of Onglyza (saxagliptin). When used in combination with metformin, the drug produced significant reductions across all key measures of the glucose control studied. Report

> A Pfizer researcher says it's getting more and more difficult to develop new medications, but that no one can do it as well as a large drugmaker can, since they have the "development muscle--the expertise, capital and leadership to design clinical trials for experimental medicines." Report

> Novartis is hoping to add another shot to the compendium of vaccines babies receive; it's working on a new meningitis B vaccine and presented data at a conference showing a positive immune response in infants. Report.

And Finally... Following generic drugmaker Mylan Inc.'s purchase of a 500-employee Dey facility from Merck, the company plans to cut some jobs and move its Napa site, which houses its commercial operations, R&D, manufacturing and administrative staff, to the East Coast.  Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.